论文部分内容阅读
据有关部门透露,近年来进口药、合资药已占我国化学药市场的1/3。截至去年底,我国共审批发放《进口药品注册证》2000余个,而实际上通过非正常渠道流入我国市场的外国药品至少占国内市场现有进口药的一半以上。在洋药长驱直入我国市场的同时,国内的外国独资、合资药品生产企业生产的合资药与洋药遥相呼应,不断扩大市场占有份额。我国的第一家中外合资药品生产企业出现于1980年,到去年底,我国医药“三资”企业已达1790余家,协议外资
According to relevant departments, imported drugs and joint venture drugs have accounted for 1/3 of China’s chemical drug market in recent years. As of the end of last year, China had approved and issued more than 2,000 “imported drug registration certificates”. In fact, foreign drugs that actually flow into China’s market through non-normal channels account for at least half of the existing imported drugs in the domestic market. At the same time as the foreign drug makers drove straight into the Chinese market, the joint venture drugs produced by domestic foreign-funded, joint-venture drug manufacturing companies echoed with Yangyao and continued to expand market share. The first Sino-foreign joint venture pharmaceutical production enterprise in China appeared in 1980, and by the end of last year, there were more than 1790 pharmaceutical and “three-funded enterprises” in China, and the foreign investment was agreed.